Deregulation of innate immune signaling in myelodysplastic syndromes is associated with deletion of chromosome arm 5q

被引：20
|
作者：
Starczynowski, Daniel T.
Karsan, Aly [1 ]
机构：
[1] BC Canc Agcy, Genome Sci Ctr, Vancouver, BC, Canada
来源：
CELL CYCLE | 2010年 / 9卷 / 05期
基金：
加拿大健康研究院;
关键词：
innate immunity; myelodysplastic syndromes; RPS14; FLI1; microRNAs; NF kappa B; IDENTIFICATION; 5Q-SYNDROME;
D O I：
10.4161/cc.9.5.11156
中图分类号：
Q2 [细胞生物学];
学科分类号：
071009 ; 090102 ;
摘要：
引用
收藏
页码：855 / 856
页数：2
相关论文
共 50 条
  • [31] Lenalidomide treatment of myelodysplastic syndromes with chromosome 5q deletion: Results from the National Registry of the Italian Drug Agency
    Arcioni, Francesco
    Roncadori, Andrea
    Di Battista, Valeria
    Tura, Sante
    Covezzoli, Anna
    Cundari, Sante
    Mecucci, Cristina
    EUROPEAN JOURNAL OF HAEMATOLOGY, 2018, 101 (01) : 78 - 85
  • [32] SOHO State of the Art and Next Questions: Management of Myelodysplastic Syndromes With Deletion 5q
    Talati, Chetasi
    Sallman, David
    List, Alan F.
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (10): : 629 - 635
  • [33] Deconstructing innate immune signaling in myelodysplastic syndromes
    Varney, Melinda E.
    Melgar, Katelyn
    Niederkorn, Madeline
    Smith, Molly A.
    Barreyro, Laura
    Starczynowski, Daniel T.
    EXPERIMENTAL HEMATOLOGY, 2015, 43 (08) : 587 - 598
  • [34] Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion
    Chesnais, Virginie
    Renneville, Aline
    Toma, Andrea
    Lambert, Jerome
    Passet, Marie
    Dumont, Florent
    Chevret, Sylvie
    Lejeune, Julie
    Raimbault, Anna
    Stamatoullas, Aspasia
    Rose, Christian
    Beyne-Rauzy, Odile
    Delaunay, Jacques
    Solary, Eric
    Fenaux, Pierre
    Dreyfus, Francois
    Preudhomme, Claude
    Kosmider, Olivier
    Fontenay, Michaela
    BLOOD, 2016, 127 (06) : 749 - 760
  • [35] Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes
    Giagounidis, Aristoteles A. N.
    SEMINARS IN HEMATOLOGY, 2012, 49 (04) : 312 - 322
  • [36] 5q– myelodysplastic syndromes: chromosome 5q genes direct a tumor-suppression network sensing actin dynamics
    K M Eisenmann
    K J Dykema
    S F Matheson
    N F Kent
    A D DeWard
    R A West
    R Tibes
    K A Furge
    A S Alberts
    Oncogene, 2009, 28 : 3429 - 3441
  • [37] Multivariate time-dependent comparison of the impact of lenalidomide in lower-risk myelodysplastic syndromes with chromosome 5q deletion
    Sanchez-Garcia, Joaquin
    del Canizo, Consuelo
    Lorenzo, Ignacio
    Nomdedeu, Benet
    Luno, Elisa
    de Paz, Raquel
    Xicoy, Blanca
    Valcarcel, David
    Brunet, Salut
    Marco-Betes, Victor
    Garcia-Pintos, Marta
    Osorio, Santiago
    Tormo, Mar
    Bailen, Alicia
    Cervero, Carlos
    Ramos, Fernando
    Diez-Campelo, Maria
    Such, Esperanza
    Arrizabalaga, Beatriz
    Azaceta, Gemma
    Bargay, Joan
    Arilla, Maria J.
    Falantes, Jose
    Serrano-Lopez, Josefina
    Sanz, Guillermo F.
    BRITISH JOURNAL OF HAEMATOLOGY, 2014, 166 (02) : 189 - 201
  • [38] Molecular Dissection of the 5q Deletion in Myelodysplastic Syndrome
    Ebert, Benjamin L.
    SEMINARS IN ONCOLOGY, 2011, 38 (05) : 621 - 626
  • [39] A NEW CRITICAL DELETION OF 5Q IN MYELODYSPLASTIC SYNDROME
    PHILLIPS, CN
    PRIEST, JH
    VOGLER, WR
    CLINICAL RESEARCH, 1984, 32 (05): : A885 - A885
  • [40] Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond
    Talati, Chetasi
    Sallman, David
    List, Alan
    SEMINARS IN HEMATOLOGY, 2017, 54 (03) : 159 - 166
12345